On Wednesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson (NYSE:JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Rybrevant Faspro is approved for all indications for which Rybrevant is approved.

Compared to intravenous (IV) delivery, Rybrevant Faspro offers significantly higher patient convenience and lower burden on healthcare resources:

Reducing administration time from several hours to five minutes (significantly less administration time than chemotherapy-based regimens, which could take up to an hour).

Demonstrating an approximately fivefold reduction in administration-related reactions (ARRs) (13% in SC vs 66% in IV arm).

Reducing venous thromboembolism (VTE) incidence (11% in SC vs 18% in IV ...